PMID-29992272 – NR Safety and Efficacy RCT in Obese Men
Dollerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, Stodkilde-Jorgensen H, Moller N, Brenner C, Treebak JT, Jessen N. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018;108(2):343-353.
Quick Reference
| Property | Value |
|---|---|
| PMID | 29992272 |
| DOI | 10.1093/ajcn/nqy132 |
| Year | 2018 |
| Journal | Am J Clin Nutr |
| Study Type | RCT |
| Evidence Level | II |
| Sample | 40 obese sedentary men (BMI >30, aged 40-70), 12 weeks |
| Peptide(s) Studied | NAD+ |
Key Findings
- NR 2000 mg/day was safe and well-tolerated over 12 weeks with no serious adverse events
- NR did NOT improve insulin sensitivity, body composition, or metabolic parameters compared to placebo
- Important safety data at high doses and a key negative-result trial informing dose-response understanding
Study Design
Randomized, double-blind, placebo-controlled trial. Forty sedentary obese men (BMI >30, age 40-70) received NR 1000 mg twice daily (2000 mg/day) or placebo for 12 weeks. Outcomes included insulin sensitivity (hyperinsulinemic-euglycemic clamp), body composition (MRI/MRS), and metabolic parameters.
Limitations
- Exclusively male cohort limits generalizability
- Lack of NAD+ metabolite measurements to confirm target engagement at these doses
Clinical Relevance
Establishes high-dose NR safety but tempers expectations for metabolic efficacy in obese populations, highlighting that NAD+ precursor supplementation may not universally improve insulin sensitivity and that dose-response relationships require further investigation.
Related
#research #RCT #evidence-level-II